Graves病合并高钙血症的发病机制及影响因素的研究
Research on the Pathogenesis and Influencing Factors of Hypercalcemia in Graves’ Disease
DOI: 10.12677/md.2025.154047, PDF,   
作者: 尹丹丹, 公义宁, 林清爱：济宁医学院临床医学院(附属医院)，山东 济宁；刘亚平*：济宁市第一人民医院内分泌与代谢科，山东 济宁
关键词: Graves病；高钙血症；影响因素；甲状腺激素；自身免疫；Graves’ Disease； Hypercalcemia； Influencing Factors； Thyroid Hormones； Autoimmunity
摘要: 格雷夫斯病(Graves’ disease, GD)作为常见的自身免疫性甲状腺疾病，常伴有多种并发症，高钙血症便是其中相对少见但不容忽视的一种。本综述旨在系统且深入地探讨GD合并高钙血症的影响因素，通过综合分析已有的研究成果，为临床诊断、治疗策略的制定以及预防措施的实施提供坚实的理论依据。相关研究表明，甲状腺激素水平的波动、自身免疫机制的异常、甲状旁腺功能的改变、维生素D代谢的失衡等多种因素相互交织，共同影响着这一并发症的发生与发展。
Abstract: Graves’ disease is a common autoimmune thyroid disease that often accompanies several complications, and hypercalcemia is one of the less common but not negligible ones. This review aims to systematically and thoroughly explore the influencing factors of hypercalcemia in Graves’ disease, by comprehensively analyzing the existing research findings, to provide a solid theoretical basis for clinical diagnosis, treatment strategy formulation, and prevention measures implementation. Related studies have shown that the fluctuation of thyroid hormone levels, abnormalities in the autoimmune mechanism, changes in the function of the parathyroid gland, and imbalances in vitamin D metabolism are intertwined and jointly affect the occurrence and development of this complication.
文章引用：尹丹丹, 公义宁, 林清爱, 刘亚平. Graves病合并高钙血症的发病机制及影响因素的研究[J]. 医学诊断, 2025, 15(4): 351-357. https://doi.org/10.12677/md.2025.154047

参考文献

[1] 陈莹, 谭婕, 李兴佳, 等. Graves病患者的促甲状腺素受体抗体与甲状腺刺激性免疫球蛋白及甲巯咪唑治疗反应的相关性[J]. 重庆医科大学学报, 2022, 47(11): 1327-1332.
[2] 刘永德, 于建成. Graves病131I治疗后早发甲减的相关因素分析[J]. 标记免疫分析与临床, 2023, 30(4): 644-648.
[3] 王超群, 匡蕾, 梁军. 肠道微生物与Graves病关系的研究进展[J]. 中国医药导报, 2023, 20(2): 43-46.
[4] 中华医学会核医学会. 131I治疗格雷夫斯甲亢指南(2021版) [J]. 中华核医学与分子影像杂志, 2021, 41(4): 243-253.
[5] Walker, M.D. and Shane, E. (2022) Hypercalcemia: A Review. JAMA, 328, 1624-1636. [Google Scholar] [CrossRef] [PubMed]
[6] 黄勤, 魏军平. Graves病发病机制研究进展[J]. 世界中医药, 2023, 18(7): 1044-1048.
[7] 赵冬, 王广. 儿童及青少年Graves病的治疗进展[J]. 医学综述, 2023, 29(6): 1164-1169.
[8] 张青, 李乐乐, 柴晓峰, 等. 甲状腺功能亢进症患者血清鸢尾素水平与Graves病的关系研究[J]. 中国全科医学, 2023, 26(8): 927-931+938.
[9] Motlaghzadeh, Y., Bilezikian, J.P. and Sellmeyer, D.E. (2021) Rare Causes of Hypercalcemia: 2021 Update. The Journal of Clinical Endocrinology & Metabolism, 106, 3113-3128. [Google Scholar] [CrossRef] [PubMed]
[10] Tonon, C.R., Silva, T.A.A.L., Pereira, F.W.L., Queiroz, D.A.R., Junior, E.L.F., Martins, D., et al. (2022) A Review of Current Clinical Concepts in the Pathophysiology, Etiology, Diagnosis, and Management of Hypercalcemia. Medical Science Monitor, 28, e935821. [Google Scholar] [CrossRef] [PubMed]
[11] Goltzman, D. (2021) Pathophysiology of Hypercalcemia. Endocrinology and Metabolism Clinics of North America, 50, 591-607. [Google Scholar] [CrossRef] [PubMed]
[12] Lugo Lopez, Z.M., Penna, L.E.M., Ortiz, A.N., Rivera, I.A., Diez, A.d.T., Bossolo, A.N.G., et al. (2021) Graves’ Disease Induced Severe Hypercalcemia. Journal of the Endocrine Society, 5, A931. [Google Scholar] [CrossRef] 
[13] 陈长军, 王秋入, 赵鑫, 等. 骨质疏松症的发病机制及临床药物治疗研究进展[J]. 重庆医科大学学报, 2024, 49(10): 1031-1038.
[14] 马兴坡, 牛敏, 申金付, 等. 甲亢患者骨代谢指标与甲状腺激素的相关性及对甲亢性疏松的预测价值[J]. 河北医学, 2021, 27(7): 1085-1090.
[15] 蒋瑞妹, 王卓群, 牛敏, 等. 骨吸收标志物β-CTX与Graves病患者并发高钙血症的相关性[J]. 中国医师杂志, 2023, 25(4): 528-531, 536.
[16] 罗文, 罗钢, 周玉玲, 等. Graves病患者血清IL-23, IL-17及Klotho蛋白水平变化及意义[J]. 现代检验医学杂志, 2022, 37 (4): 178-182.
[17] Dadu, R., et al. (2020) Calcium-Sensing Receptor Autoantibody-Mediated Hypoparathyroidism Associated with Immune Checkpoint Inhibitor Therapy: Diagnosis and Long-Term Follow-Up. Journal for Immunotherapy of Cancer, 8, e000687. [Google Scholar] [CrossRef] [PubMed]
[18] Fux-Otta, C., Reynoso, R., Chedraui, P., Estario, P., Estario, M.E., Iraci, G., et al. (2024) Clinical and Molecular Evaluation of Insulin Autoimmune Syndrome in a Woman with Graves’ Disease Who Subsequently Became Pregnant: A Case Report. Case Reports in Women’s Health, 43, e00644. [Google Scholar] [CrossRef] [PubMed]
[19] Maruotti, N., Corrado, A., Rotondo, C. and Cantatore, F.P. (2019) Janus Kinase Inhibitors Role in Bone Remodeling. Journal of Cellular Physiology, 235, 1915-1920. [Google Scholar] [CrossRef] [PubMed]
[20] Kaur, K., Batra, N., Kadian, K. and Sridharan, K. (2022) Hypercalcaemia as the Initial Presentation of Graves’ Disease. BMJ Case Reports, 15, e251454. [Google Scholar] [CrossRef] [PubMed]
[21] Mura, C., Sonnino, R., Crispino, L., Rota, C.A. and Pontecorvi, A. (2024) Graves’ Disease in Hypopituitarism Due to Pituitary Apoplexy. Endocrine, Metabolic & Immune Disorders—Drug Targets, 24, 21. [Google Scholar] [CrossRef] [PubMed]
[22] Huang, F., Zhang, L., Zhou, Y., Zhao, S. and Wang, J. (2024) NrCAM Activates the NF-κB Signalling Pathway by Competitively Binding to SUMO‐1 and Promotes Th17 Cell Differentiation in Graves’ Disease. Scandinavian Journal of Immunology, 100, e13401. [Google Scholar] [CrossRef] [PubMed]
[23] Vogt, A.Z. and Vrcek, I.M. (2024) Use of Oxymetazoline Hydrochloride Ophthalmic Solution, 0.1% for Improved Lid Symmetry in Graves’ Disease. Orbit, 44, 34-38. [Google Scholar] [CrossRef] [PubMed]
[24] Smith, T.J., Holt, R.J., Fu, Q., Qashqai, A., Barretto, N., Conrad, E., et al. (2024) Assessment of Hearing Dysfunction in Patients with Graves’ Disease and Thyroid Eye Disease without or with Teprotumumab. The Journal of Clinical Endocrinology & Metabolism, 110, 811-819. [Google Scholar] [CrossRef] [PubMed]
[25] Berger, J.M. and Karsenty, G. (2022) Osteocalcin and the Physiology of Danger. FEBS Letters, 596, 665-680. [Google Scholar] [CrossRef] [PubMed]
[26] Gillet, M., Vasikaran, S. and Inderjeeth, C. (2021) The Role of PINP in Diagnosis and Management of Metabolic Bone Disease. Clinical Biochemist Reviews, 42, 3-10. [Google Scholar] [CrossRef] [PubMed]
[27] Kefeli, M., Gucer, H., Durmus, E.T., Atmaca, A., Colak, R. and Mete, O. (2024) Prevalence of Papillary Thyroid Carcinoma Is Significantly Higher in Graves Disease with Synchronous Thyroid Nodules. Turkish Journal of Pathology, 40, 190-195. [Google Scholar] [CrossRef] [PubMed]
[28] Zavaleta, C.J.M., Aldave, Q.E.J., Fabián, R.E.K., et al. (2024) Methimazole-Induced Pancytopenia in a Patient with Graves’ Disease: A Case Report and Literature Review. Current Drug Safety, 20, 371-376.
[29] Schiavone, D., Crimì, F., Cabrelle, G., Pennelli, G., Sacchi, D., Mian, C., et al. (2024) Role of Lugol Solution before Total Thyroidectomy for Graves’ Disease: Randomized Clinical Trial. British Journal of Surgery, 111, znae196. [Google Scholar] [CrossRef] [PubMed]
[30] Cai, H., Chen, S., Jiang, Z., Chen, L. and Yang, X. (2024) PTPN22 through the Regulation of Th17/Treg Balance Acts as a Potential Target for the Treatment of Graves’ Disease. Tissue and Cell, 90, Article ID: 102502. [Google Scholar] [CrossRef] [PubMed]
[31] Lanzolla, G., Marinò, M. and Menconi, F. (2024) Graves Disease: Latest Understanding of Pathogenesis and Treatment Options. Nature Reviews Endocrinology, 20, 647-660. [Google Scholar] [CrossRef] [PubMed]
[32] Kartini, D. and Dini, M.A.R. (2024) Pediatric Graves’ Disease: Surgical Interventions in a Single Institution—A Comprehensive Case Series. Indian Journal of Otolaryngology and Head & Neck Surgery, 76, 4846-4850. [Google Scholar] [CrossRef] [PubMed]
[33] Silva, B.C.A., Damas, I.I., Moma, A.C., et al. (2024) Lower Proportion of Intra-Thyroidal B Lymphocytes CD20+ Associated to Methimazole and Lack of Influence of Iodide on Lymphocyte Subpopulations in Graves’ Disease. Molecular and Cellular Endocrinology, 592, Article ID: 112331.